These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 15215494)
21. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. Chappell BJ; Margot NA; Miller MD AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698 [TBL] [Abstract][Full Text] [Related]
22. Current and future management of treatment failure in low- and middle-income countries. Boyd MA Curr Opin HIV AIDS; 2010 Jan; 5(1):83-9. PubMed ID: 20046152 [TBL] [Abstract][Full Text] [Related]
23. Resistance to HIV drugs in UK may be lower in some areas. Fox JM; Fidler S; Weber J BMJ; 2006 Jan; 332(7534):179-80. PubMed ID: 16424507 [No Abstract] [Full Text] [Related]
24. [HIV drug resistance]. Marcelin AG; Calvez V Rev Prat; 2006 May; 56(9):978-86. PubMed ID: 16775978 [TBL] [Abstract][Full Text] [Related]
26. Generic HIV drugs--enlightened policy for global health. Wainberg MA N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804 [No Abstract] [Full Text] [Related]
27. Recent highlights in clinical AIDS research. Laurence J AIDS Read; 2008 Feb; 18(2):64-6. PubMed ID: 18330032 [No Abstract] [Full Text] [Related]
29. Will ART rollout in Africa drive an epidemic of drug resistant HIV? Hastings IM; Lalloo D; Khoo SH AIDS; 2006 Jun; 20(9):1354-6; author reply 1356-7. PubMed ID: 16816578 [No Abstract] [Full Text] [Related]
30. Antiretroviral drug resistance among HIV-1 infected children failing treatment. Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814 [TBL] [Abstract][Full Text] [Related]
31. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. Lwembe R; Ochieng W; Panikulam A; Mongoina CO; Palakudy T; Koizumi Y; Kageyama S; Yamamoto N; Shioda T; Musoke R; Owens M; Songok EM; Okoth FA; Ichimura H J Med Virol; 2007 Jul; 79(7):865-72. PubMed ID: 17516531 [TBL] [Abstract][Full Text] [Related]
32. The marriage of science and optimized HIV care in resource-limited settings. Calmy A; Pizzocolo C; Pizarro L; Brücker G; Murphy R; Katlama C; AIDS; 2008 Nov; 22(17):2227-30. PubMed ID: 18981761 [No Abstract] [Full Text] [Related]
33. Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS. Coovadia H N Engl J Med; 2004 Jul; 351(3):289-92. PubMed ID: 15247337 [No Abstract] [Full Text] [Related]
34. Perspectives on treatment failure with thymidine analogue-based first-line regimens in resource-limited settings. Riedel DJ; Amoroso A Clin Infect Dis; 2009 Dec; 49(12):1958-9. PubMed ID: 19929390 [No Abstract] [Full Text] [Related]
35. Glaxo cuts HIV drug cost for developing world. Nature; 1998 Mar; 392(6672):118. PubMed ID: 9515951 [No Abstract] [Full Text] [Related]
36. COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings. Hetherington S Pediatr Infect Dis J; 2009 Jan; 28(1):41-2. PubMed ID: 19057455 [TBL] [Abstract][Full Text] [Related]
37. Rationing antiretroviral therapy in Africa--treating too few, too late. Ford N; Mills E; Calmy A N Engl J Med; 2009 Apr; 360(18):1808-10. PubMed ID: 19403900 [No Abstract] [Full Text] [Related]